Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MYOMO INC-NEW | 3 | Q2 2024 | 7.9% |
DELCATH SYSTEMS, INC. | 3 | Q2 2024 | 11.9% |
XERIS BIOPHARMA HLDGS INC | 3 | Q2 2024 | 6.9% |
MEDIWOUND LTD-NEW | 3 | Q2 2024 | 6.5% |
OPTINOSE INC | 3 | Q2 2024 | 6.2% |
LYRA THERAPEUTICS INC | 3 | Q2 2024 | 8.2% |
COMPASS PATHWAYS PLC ADR | 3 | Q2 2024 | 5.8% |
VIRIDIAN THERAPEUTICS INC | 3 | Q2 2024 | 6.5% |
CELLECTAR BIOSCIENCES-NEW | 3 | Q2 2024 | 5.2% |
PROFOUND MEDICAL CORP-NEW | 3 | Q2 2024 | 4.3% |
View Rosalind Advisors, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Biofrontera Inc. | May 29, 2024 | 504,261 | 9.9% |
KIORA PHARMACEUTICALS INC | May 29, 2024 | 2,300,000 | 9.9% |
OptiNose, Inc. | May 29, 2024 | 7,547,148 | 7.8% |
DELCATH SYSTEMS, INC. | May 17, 2024 | 2,763,468 | 9.9% |
SPRUCE BIOSCIENCES, INC. | April 25, 2024 | 1,508,419 | 3.7% |
PolyPid Ltd. | March 01, 2024 | 415,800 | 10.0% |
GUIDED THERAPEUTICS INCSold out | February 20, 2024 | 0 | 0.0% |
Sientra, Inc.Sold out | February 20, 2024 | 0 | 0.0% |
MYOMO, INC. | August 28, 2023 | 2,611,418 | 9.8% |
PhaseBio Pharmaceuticals Inc | February 14, 2022 | 707,467 | 1.5% |
View Rosalind Advisors, Inc.'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-08-14 |
SC 13G/A | 2024-08-14 |
13F-HR | 2024-07-12 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-07-11 |
SC 13G/A | 2024-05-29 |
View Rosalind Advisors, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.